SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- ...
SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are ...
Nassau County drug rehab now offers monthly Sublocade and Vivitrol injections for opioid and alcohol addiction on Long ...
The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...
Model estimates SUBLOCADE ® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons ; RICHMOND, Va., March 31, 202 ...
RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches ...
This retrospective study includes clinical case studies from four pregnant patients treated with monthly SUBLOCADE, postmarketing surveillance data covering more than five years, and a targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results